News

Treatment with a novel one-time gene therapy improved motor function and extended survival in a mouse model of amyotrophic lateral sclerosis (ALS) driven by mutations in the SOD1 gene, according to researchers from the University of Massachusetts Chan Medical School. The results, the team noted,…

A panel of 19 blood proteins may help estimate when symptoms of amyotrophic lateral sclerosis (ALS) will emerge in people who carry disease-associated genetic variants, a new study suggests. When the model was tested using data from carriers whose symptom-onset dates were known, its estimates differed from the actual timing…

For people serving in the U.S. armed forces, the risk of developing amyotrophic lateral sclerosis (ALS) varies by military branch and rank, a study suggested. The study found the risk of ALS is lower among people in the Marines or Army than among those who served in the Coast…

Mutations in the NEK1 gene — a major genetic cause of amyotrophic lateral sclerosis (ALS) — can disrupt the molecular machinery that cells normally rely on to make new proteins, according to a new study. The results shed new light on the molecular mechanisms by which certain mutations can contribute…

Abnormal levels of certain fatty molecules in the body — which are broken down by metabolism to support daily functions —may increase the risk of amyotrophic lateral sclerosis (ALS), according to a new study. The research, which was based on genetic data to reduce the influence of external factors,…

People whose amyotrophic lateral sclerosis (ALS) begins with speech and swallowing problems, known as bulbar onset, are typically diagnosed about four months sooner than those whose disease begins with arm or leg weakness, known as limb onset. That’s according to a pooled analysis of data from 13 studies across…

Neurosense Therapeutics announced that it’s preparing a new drug submission to Health Canada — following a meeting with the regulatory agency — to seek approval of PrimeC, its combination therapy for amyotrophic lateral sclerosis (ALS), in the North American nation. During that meeting, the U.S. biotech company presented…

The U.S. House of Representatives has passed legislation that would renew the ACT for ALS, a landmark federal law that supports amyotrophic lateral sclerosis (ALS) research and helps people with the disease access promising experimental therapies. The ACT for ALS Reauthorization Act (H.R. 8205) will now move to…

A stem cell therapy conditionally approved in South Korea for treating amyotrophic lateral sclerosis (ALS) will remain available in the Asian nation despite failing to meet the main goal of a late-stage clinical trial that sought to confirm its effectiveness. Developer Corestemchemon announced that Neuronata-R (lenzumestrocel) will…

The Muscular Dystrophy Association (MDA) brought its Engage Community Seminar to Hershey, Pennsylvania, on July 18, uniting individuals with neuromuscular diseases, caregivers, and medical experts for a day of education and connection. Hosted in collaboration with the Penn State Health Milton S. Hershey Medical Center, the one-day event featured a…